Mountain Valley MD Pursues Ambitious Initiatives, Including Partnership With FDA Monday, July 12, 2021 1:16 AM UTC
The COVID-19 pandemic has put the spotlight squarely on medical, pharmaceutical and biotechnology companies that work to create solutions for these medical issues. One standout in this field is Mountain Valley MD (MVMD), which has recently announced a number of important initiatives to help in the treatment of a variety of illnesses and medical conditions. The International Business Times recently published an article exploring the many ambitious projects currently underway at MVMD and praising the company for its many accomplishments.
MVMD was founded in 2018 and has rapidly risen to the top of the biotechnology field thanks to its innovative approaches to some of the most challenging issues facing the medical community today. The company has created a number of proprietary solutions that have made it
Mountain Valley MD Commencing Trials in Bangladesh, Striking Pharmaceutical Production Agreements
News provided by
Share this article
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials under the supervision of The People s Republic of Bangladesh s Ministry of Fisheries & Livestock for the Company s injectable solubilized Ivermectin technology, Ivectosol™ 1%. We are very excited to be welcoming Mountain Valley MD to The People s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product, stated Bangladesh s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.